Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Transfer Factor”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed1980

Transfer factor in treatment of multiple sclerosis.

A 2-year prospective double-blind trial of the treatment of multiple sclerosis patients with the leucocyte extract, transfer factor (TF), obtained from leucocytes of relatives living with the patient, was conducted. 60 patients with definite MS, of whom 58 completed the trial, were divided into two equal groups, one of which received TF and the other placebo. The groups were evenly balanced with respect to sex ratios, disability, duration of disease, ratio of moderate to severe cases, and HLA phenotype. Neurological, electrophysiological, and immunological assessments were done at the start of the trial and every 6 months thereafter. The results indicated that (1) TF retarded but did not reverse progression of the disease; (2) a significant difference between treatment and placebo groups was not apparent with 18 months after the start of the trial; and (3) treatment was effective only in those patients with mild to moderate disease activity.

Adolescent↗
PubMed1984

The effect of transfer factor treatment on two challenge infections of Haemonchus contortus in immuno-competent 7-month-old lambs.

A number of immuno-competent Blackface lambs were infected with 10,000 Haemonchus contortus third stage larvae and were later challenged with a second dose of 10,000 H. contortus third stage larvae. One group of lambs was treated with dialysed transfer factor prior to the second challenge dose. Histological changes in the abomasal wall, reductions in abomasal worm burdens at slaughter and faecal egg counts monitored throughout the experiment suggested the presence in some animals of an innate resistance, a "self curing" effect, an enhancement of this "self curing" effect in the transfer factor treated group and a response in one transfer factor treated animal comparable to "classical self cure".

Abomasum↗
PubMed1984

Adoptive transfer of delayed hypersensitivity and protective immunity to Eimeria tenella with chicken-derived transfer factor.

Delayed hypersensitivity (DH) and protective immunity were transferred to nonimmune 4- and 10-week-old broiler chickens with transfer factor (TF) prepared from splenic leukocytes of chickens immunized with CocciVac D. Only chickens injected with the immune TF showed DH by wattle reaction to oocyst antigen and protective immunity to Eimeria tenella challenge infection. Chickens given a single injection of TF 5 days before challenge infection exhibited a significant (P less than .05) DH response at the time of infection. Immune TF preparations were active at concentrations of 100, 200, or 400 mg. Neither DH nor protective immunity was transferred to chickens injected with the TF-diluent control or nonimmune TF. The nonimmune TF was prepared from chickens kept free of coccidial infection. These findings indicated that TF prophylaxis produced beneficial results in nonimmune chickens by conferring some protection against challenge with E. tenella. The effects of TF on T-lymphocyte mediated protective immunity to coccidia in chickens are discussed.

Animals↗
PubMed1976

In vivo and in vitro studies of immunotherapy of nasopharyngeal carcinoma with transfer factor.

Epstein-Barr virus, the apparent cause of infectious mononucleosis, may also be an etiological agent in nasopharyngeal carcinoma and Burkitt's lymphoma. Lymphocytes from normal individuals with anti-Epstein-Barr virus antibody activity may be sensitized to Epstein-Barr virus and contain transfer factor with the potential to program and/or recruit other lymphocytes to react against the virus and/or viral antigens. A patient with nasopharyngeal carcinoma refractory to conventional therapy was treated with transfer factor obtained from normal, young adults with previous history of infectious mononucleosis. Following immunotherapy, apparent slowing of tumor growth was observed, which was associated with intense lymphocytic infiltration of the tumor and reconstitution of delayed cutaneous hypersensitivity reactions to microbial recall antigens. A double-blind randomized clinical trial has been initiated to determine whether transfer factor immunotherapy is a useful adjunct to radiotherapy in the primary treatment of patients with nasopharyngeal carcinoma. If successful, a similar trial might be considered for African patients with Burkitt's lymphoma.

Adult↗
PubMed1993

[Effect of hepatocellular carcinoma-specific transfer factor (HCC-S-TF) on IL-2 activity and IL-2R expression].

HCC specific transfer factor (S-TF) was extracted from lymphoid tissues of goats immunized with HCC cell suspension. The effect of the S-TF on IL-2 activity and IL-2R expression was observed in vitro. The results showed that IL-2 activity and IL-2R expression in HCC patients but not in normal subjects could be increased by the S-TF. The IL-2 activities and IL-2R expressions in both normal subjects and patients with HCC could not be increased by normal transfer factor (N-TF). This may be one of the anti-tumor mechanisms of S-TF. It suggests that S-TF may be better than N-TF in immunotherapy of human tumors.

Adult↗
PubMed1998

[The adjuvant and specific activity of transfer factors to Candida albicans antigens].

Activity of transfer-factor (TF) delayed type hypersensitivity in allogenic and xenogeneic have studied. Guinea pigs was been sensibilized Soluble antigens and whole cells Candida albicans for production TF. Both TF expressed non specific and specific activity in the guinea pig and mouse leucocytes inhibition migration in vitro and delayed type hypersensitivity in mica. Activity of TF to cellular antigen was lower then TF to soluble antigen in xenogeneic systems. However TF activity was some low for whole cells in xenogeneic systems.

Adjuvants, Immunologic↗
PubMed1985

The study of human transfer factor.

In this paper, the study of human transfer factor is reported. We established a negative pressure dialysis method instead of ordinary dialysis for treatment of the crude leukocyte extract. Dialysate is rapidly obtained in only 5 h so that a large volume of preparation is easier to handle and the chance of contamination avoided. When human TF was incubated with human cord blood T-lymphocytes and pig lymphocytes, a very high biological activity on SRBC rosette enhancement and an increase in electrophoresis rate appeared. It suggests that these assays may be used as in vitro method of evaluation of TF activity. In our clinic, TF has been in clinical trials for 5 years and has now been administered to a large number of patients with a variety of diseases, in which cell-mediated immune responses have been compromised. We observe that TF has served an efficient immunopotentiating or immunomodulation agent.

Adjuvants, Immunologic↗
PubMed1984

Transfer factor and repeated otitis media.

The effect of transfer factor (TF) was investigated in 12 children with repeated otitis media. These patients were immunologically compared to a control group of 23 age-matched healthy children. Levels of immunoglobulins, total and "active" T-cells, and phagocytic activity of granulocytes and monocytes were evaluated in the 12 children prior to, during, and after TF therapy. Percentages of "active" T cells and absolute numbers of "active" T and total T cells, which were initially low in the patient group, increased significantly after TF therapy to statistically match those of the healthy control group. The percentage of phagocytic monocytes in patients after therapy did not differ from healthy children; however, the percentage of phagocytic granulocytes remained depressed significantly. The levels of IgG, IgA, and IgM were unaffected by the therapy although the IgA and IgM were higher in the patient population throughout the study. After therapy, one-half of the patient population remained asymptomatic for a 1-year period and the others had markedly reduced attack rates.

Child↗
PubMed1995

Effect of Brucella abortus transfer factor in preventing murine brucellosis.

Mice vaccinated with a protein extract of attenuated Brucella abortus strain 19 had increased resistance to infection with virulent B. abortus strain 2308 and had increased antibody responses to strain 2308. However, resistance to infection and antibody responses were not increased when nonvaccinated recipient mice were given transfer factor preparations that were obtained from either vaccinated donor mice or strain 2308-infected donor mice. Vaccination of mice with the strain 19 extract plus treatment with each transfer factor preparation also did not further increase resistance to infection or antibody responses when compared with mice that received the vaccine alone. These results suggest that transfer factor from mice that have either vaccine-induced protective immunity to B. abortus or active B. abortus infections does not enhance antibody responses and resistance to infection with B. abortus.

Animals↗
PubMed1975

Breathlessness and transfer factor for the lung in chronic obstructive lung disease.

The breath-holding CO transfer factor and transfer coefficient were correlated with the severity of dyspnea in 37 patients with moderate or severe obstructive lung disease FEV 1.0 less than 1.5 1) No correlation was evident when the whole group was considered. When the patients were subdivided into "bronchitics", "intermediate" and "emphysematous" a correlation between dyspnea severity and gas transfer appeared for the latter subgroup; this correlation was statistically significant for the transfer coefficient.

Age Factors↗
PubMed1977

Transposition and insertion of intact, deleted and enlarged ampicillin transposon Tn3 from mini-R1 (Rsc) plasmids into transfer factors.

The miniR1-(Rsc)-plasmids which derive from the copy mutant R1drd-19B2 (pKN102) are non-conjugative extrachromosomal elements which can not be co-transferred by various transfer factors to recipient strains under standard mating conditions. The attempts to mobilize Rsc11 by F'lac lead to transconjugants carrying F'lac::Tn3 with Tn3 mainly inserted into the lac operon. In addition it can be shown that Rsc11 can become inserted as a complete unit into the transfer factor giving rise to rather unstable recombinant intermediates. Dissociation of these intermediates may lead to alterations of the original plasmids. The Tn3 part of Rsc13 can be enlarged or deleted by in vitro manipulations. In vitro insertion of EcoRI-fragments into an EcoRI+ site of Tn3 leads to new transposable units which can be transposed to the RTF part of R1. This new genetic entity can be stably integrated into the chromosome of E. coli by integrative suppression of a dnaAts-mutation. Deletions at one end or the central region of Tn3 abolish the capability of transposition. However, the Rsc-plasmids containing the deleted Tn3 can still be inserted into the transfer factor as complete units. The resulting recombinants are unstable leading after dissociation in some cases to new plasmids with altered properties.

Ampicillin↗
PubMed1975

Wiskott-Aldrich syndrome with 18-year survival. Treatment with transfer factor.

An 18-year-old boy with Wiskott-Aldrich syndrome has severe symptoms of thrombocytopenia, recurrent infections, and atopic eczema. We believe he is the fifth oldest patient described with Wiskott-Aldrich syndrome. Recently, a malignant lymphoma of the histiocytic type appeared in the skin, while he was receiving transfer factor. To our knowledge, he is the only reported patient with lymphoma in the skin, but four other patients with Wiskott-Aldrich syndrome have developed malignant lymphoreticular lymphoma during transfer factor therapy. Detailed immunologic studies show failure to make a sustained antibody response to various antigens, lack of delayed hypersensitivity responsiveness, and failure of proliferative response to antigens in in vitro cultures. The IgE and IgA levels were high, and the IgM and IgG levels were low. Although clinical improvement followed transfer factor therapy, development of the malignant lymphoma was not prevented.

Adolescent↗
PubMed1975

T-cell reconstitution by thymus transplantation and transfer factor in severe combined immunodeficiency.

Reconstitution of cell-mediated immunity was achieved in a 5-month old female infant with severe combined immunodeficiency by fetal thymus transplant given simultaneously with two units of transfer factor. Thymus was obtained from a 15-week gestational age male fetus, and the two units of transfer factor from the lymphocytes of 500 ml of peripheral blood. Three weeks after transplantation, two nel HL-A antigens were detected on the infant's lymphocytes, one of which was present in the mother of the thymus donor; at the same time, some of the infant's own HL-A antigens disappeared. Thereafter, the percent of rosette-forming cells (T-cells) increased and the in vitro response to phytohemagglutinin and allogeneic lymphocytes became normal, and delayed skin tests became positive. Karyotyping of peripheral blood lymphocytes posttransplantation reveals an XY (male) pattern. These results suggest lymphocyte re-population as a result of the thymus-transfer factor therapy. Five months after transplantation, the patient has normal cellular immunity but persistent hypogammaglobulinemia. She is free of infection and growing normally on gammaglobulin injections.

Female↗
PubMed1983

Relation of pulmonary vessel size to transfer factor in subjects with airflow obstruction.

In a group of 61 consecutive patients undergoing assessment of airflow obstruction, a significant linear relation was demonstrated between measurements of the diameter of the midzonal pulmonary vessels on the plain chest radiographs and transfer factor (diffusing capacity for carbon monoxide) (r = 0.46, p less than 0.001). Since reduction in transfer factor has been shown to relate to structural emphysema, reduction in midzone vessel caliber implies the same. However, in the individual patient neither the transfer factor nor structural emphysema can be reliably predicted from midzone vessel diameters alone.

Carbon Monoxide↗
PubMed1991

Combination therapy with transfer factor and high dose stronger neo-minophagen C in chronic hepatitis B in children (HBe Ag positive).

This study mainly describes the efficacy of the combination therapy with Transfer Factor (TF) and high dose Stronger Neo-Minophagen C (SNMC) for HBV carrier children with HBe Ag positive chronic hepatitis. There were 12 patients, 10 males and 2 females aged from 7 months to 14 years 8 months. Liver biopsy was done in 11 patients, and the histopathological findings of the liver were chronic active hepatitis (8 cases) and chronic inactive hepatitis (3 cases). In 6 of 8 patients, HBe-Ag became negative (75%) within 18 weeks (mean 8 weeks) after the initiation of the combination therapy with TF and SNMC (HBe-seronegative), and 4 of these 8 patients (50%) became anti-HBe positive within 29 weeks (mean 15 weeks) (HBe-seroconversion). These results suggest that combination therapy with TF and high dose SNMC may be beneficial in the treatment of chronic hepatitis B in children.

Adolescent↗
PubMed2007

Transfer of chemicals from feed to animal products: The use of transfer factors in risk assessment.

The human risk assessment of feed contaminants has often been hampered by a lack of knowledge concerning their behaviour when consumed by livestock. To gain a better understanding of the transfer of contaminants from animal feed to animal products, a meta-analysis of public literature was made. Data concerning feed contaminant concentrations, feeding periods, residue levels in animal products, and other parameters were gathered and recorded. For each case a 'transfer factor', which was defined as the ratio of the concentration of a chemical in an animal product to the concentration of the chemical in animal feed, was calculated. Scientifically founded transfer factors were calculated and analysed for groups of chemicals based on their contaminant classes or physicochemical properties. These database-derived transfer factors enable a more accurate risk assessment in the case of a feed contamination, and enable rapid risk management decision-making and/or intervention.

Animal Feed↗
PubMed2005

Is the transfer factor a relevant tool to assess the soil-to-plant transfer of radionuclides under field conditions?

The radiological impact of radionuclides released to the terrestrial environment is usually predicted with mathematical models in which the transfer of radionuclides from soil to the plant is described with the transfer factor (TF). This paper questions the validity of the protocols proposed by the International Atomic Energy Agency to measure TF in the field and in greenhouses conditions. We grew maize (Zea mays L.) both in the field after a surface application of radionuclides ((54)Mn, (57)Co, (65)Zn, and (134)Cs) and in a greenhouse with the same soil that has received the same fertilization and that had been previously sieved and homogeneously labeled with the same radionuclides before being repacked in pots. The analysis of the displacement of radionuclides in the field soil profile showed a higher concentration of the surface-applied radionuclides in the preferential flow path (PFP) in comparison to the soil matrix indicating that they infiltrated heterogeneously in the soil profile due to the structure-induced non-uniform water flow. A significantly higher recovery of (57)Co and (134)Cs was observed in the plants grown in the field soil, whereas no differences in the recovery of (54)Mn and (65)Zn between the two experiments were detected. These results suggest that (i) under field conditions the soil-to-plant transfer of radionuclides that co-exist as stable elements present at low concentrations in the soil and in the plant is higher than that measured under greenhouse conditions and (ii) the implicit assumption made when calculating the TF (that radionuclides are homogeneously distributed in the soil profile) is not valid, thereby preventing the calculation of an average concentration to obtain the TF parameter.

Models, Theoretical↗